These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 807758

  • 21. Antimicrobial activity of fosfomycin in vitro.
    Forsgren A, Walder M.
    J Antimicrob Chemother; 1983 May; 11(5):467-71. PubMed ID: 6874631
    [Abstract] [Full Text] [Related]

  • 22. Immunomodulating effect of fosfomycin on gut-derived sepsis caused by Pseudomonas aeruginosa in mice.
    Matsumoto T, Tateda K, Miyazaki S, Furuya N, Ohno A, Ishii Y, Hirakata Y, Yamaguchi K.
    Antimicrob Agents Chemother; 1997 Feb; 41(2):308-13. PubMed ID: 9021184
    [Abstract] [Full Text] [Related]

  • 23. [Antibacterial activities of fosfomycin against several fresh clinical isolates--comparison of the test methods for antibacterial activity].
    Hara T, Araake M, Watabe H.
    Jpn J Antibiot; 2002 Dec; 55(6):844-54. PubMed ID: 12621737
    [Abstract] [Full Text] [Related]

  • 24. [Comparative effectiveness of gentamycin and other antibiotics in experiment].
    Navashin SM, Fomina IP, Kuznetsova SM.
    Antibiotiki; 1969 Aug; 14(8):716-21. PubMed ID: 4314051
    [No Abstract] [Full Text] [Related]

  • 25. Synergistic effects of a macrolide and a cell wall-affecting antibiotic on Pseudomonas aeruginosa in vitro and in vivo. 2. Combined effects of a macrolide with a fosfomycin and an aminoglycoside antibiotic.
    Kasai T, Homma JY.
    J Antibiot (Tokyo); 1982 Jul; 35(7):858-65. PubMed ID: 6816781
    [Abstract] [Full Text] [Related]

  • 26. [Antibacterial activity of a new semisynthetic aminoglycoside antibiotic amikacin (BB-K8) (author's transl)].
    Mitsuhashi S, Kawabe H, Iyobe S, Tanaka T, Inoue M.
    Jpn J Antibiot; 1974 Apr; 27(2):189-92. PubMed ID: 4211300
    [No Abstract] [Full Text] [Related]

  • 27. Small-Molecule Inhibitor of FosA Expands Fosfomycin Activity to Multidrug-Resistant Gram-Negative Pathogens.
    Tomich AD, Klontz EH, Deredge D, Barnard JP, McElheny CL, Eshbach ML, Weisz OA, Wintrode P, Doi Y, Sundberg EJ, Sluis-Cremer N.
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642934
    [Abstract] [Full Text] [Related]

  • 28. In vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria.
    Khan IU, Mirza IA, Ikram A, Ali S, Hussain A, Ghafoor T.
    J Coll Physicians Surg Pak; 2014 Dec; 24(12):914-7. PubMed ID: 25523727
    [Abstract] [Full Text] [Related]

  • 29. [Update on antibiotic therapy. 17) A combination of fosfomycin and cephalexin (cefemic cofosfolactamine)].
    Di Nola F.
    Minerva Med; 1983 May 12; 74(20):1217-22. PubMed ID: 6379514
    [No Abstract] [Full Text] [Related]

  • 30. [Antibacterial effect of rifampicin and its chemotherapeutic properties in experiments on animals].
    Shorin VA, Shapovalova SP, Malkova IV.
    Antibiotiki; 1974 Dec 12; 19(12):1084-8. PubMed ID: 4155605
    [No Abstract] [Full Text] [Related]

  • 31. The effect of trimethoprim on the activity of sulfonamides and antibiotics in experimental infections.
    Grunberg E.
    J Infect Dis; 1973 Nov 12; 128():Suppl:478-85 p. PubMed ID: 4202205
    [No Abstract] [Full Text] [Related]

  • 32. Role of ciprofloxacin in its synergistic effect with fosfomycin on drug-resistant strains of Pseudomonas aeruginosa.
    Yamada S, Hyo Y, Ohmori S, Ohuchi M.
    Chemotherapy; 2007 Nov 12; 53(3):202-9. PubMed ID: 17356268
    [Abstract] [Full Text] [Related]

  • 33. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey.
    Demir T, Buyukguclu T.
    Int J Infect Dis; 2013 Nov 12; 17(11):e966-70. PubMed ID: 23742831
    [Abstract] [Full Text] [Related]

  • 34. [Comparison of susceptibilities for fosfomycin determined by various methods in clinical isolates in 2003 -2004].
    Muramatsu H, Ishikawa J, Nagura O, Horii T.
    Jpn J Antibiot; 2007 Apr 12; 60(2):107-24. PubMed ID: 17612258
    [Abstract] [Full Text] [Related]

  • 35. In vitro and in vivo antibacterial activity of FR-31564, a phosphonic acid antimicrobial agent.
    Neu HC, Kamimura T.
    Antimicrob Agents Chemother; 1981 Jun 12; 19(6):1013-23. PubMed ID: 7271270
    [Abstract] [Full Text] [Related]

  • 36. [Bacteriological study on fosfomycin against organisms clinically isolated from paranasal sinusitis].
    Deguchi K, Yokota N, Koguchi M, Nakane Y, Suzuki Y, Fukayama S, Ishihara R, Oda S.
    Jpn J Antibiot; 1991 Aug 12; 44(8):813-9. PubMed ID: 1920807
    [Abstract] [Full Text] [Related]

  • 37. Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study.
    Pan AJ, Mei Q, Ye Y, Li HR, Liu B, Li JB.
    J Antibiot (Tokyo); 2017 Feb 12; 70(2):166-173. PubMed ID: 27756910
    [Abstract] [Full Text] [Related]

  • 38. [Antibiotic effect of extracts from Agrimonia-variety].
    Péter HM.
    Pharmazie; 1969 Oct 12; 24(10):632-5. PubMed ID: 4391804
    [No Abstract] [Full Text] [Related]

  • 39. In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
    Fernandes PB, Chu DT, Bower RR, Jarvis KP, Ramer NR, Shipkowitz N.
    Antimicrob Agents Chemother; 1986 Feb 12; 29(2):201-8. PubMed ID: 3521473
    [Abstract] [Full Text] [Related]

  • 40. The revival of fosfomycin.
    Michalopoulos AS, Livaditis IG, Gougoutas V.
    Int J Infect Dis; 2011 Nov 12; 15(11):e732-9. PubMed ID: 21945848
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.